comparemela.com

Latest Breaking News On - Counter analysis system - Page 1 : comparemela.com

MicroRNAs Predict Pancreatic Cancer Risk Years in Advance

NanoString Technologies (NASDAQ:NSTG) versus Adaptimmune Therapeutics (NASDAQ:ADAP) Head-To-Head Survey

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and NanoString Technologies (NASDAQ:NSTG – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Valuation and Earnings This table compares Adaptimmune […]

NanoString Technologies (NASDAQ:NSTG) Coverage Initiated at StockNews com

StockNews.com began coverage on shares of NanoString Technologies (NASDAQ:NSTG – Get Free Report) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock. NanoString Technologies Stock Performance The firm has a market capitalization of $5.07 million, a price-to-earnings ratio of -0.03 and a beta of 1.24. The […]

NanoString Technologies, Inc (NASDAQ:NSTG) Receives $7 63 Consensus Price Target from Analysts

Shares of NanoString Technologies, Inc. (NASDAQ:NSTG – Get Free Report) have been assigned a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 […]

NanoString Technologies (NASDAQ:NSTG) Research Coverage Started at StockNews com

Analysts at StockNews.com assumed coverage on shares of NanoString Technologies (NASDAQ:NSTG – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock. Separately, JPMorgan Chase & Co. lowered NanoString Technologies from an “overweight” rating to a “neutral” rating in a […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.